PGCX PanGenex Corporation

[MATTO]

TAMPA, Fla.--(BUSINESS WIRE)--PanGenex Corporation (Pink Sheets:PGCX - News), a global nutraceutical and dietary supplement manufacturer and marketer, is pleased to announce today that two of the nation's leading interventional cardiologists, Dr. Steven Yakubov and Dr. Mark Turco, have joined the Company's Scientific Advisory Board.


The PanGenex Scientific Advisory Board functions to assist in product development and clinical testing, as well as helping to direct the Company’s marketing practices to physicians and their peers in the U.S. and abroad. “Consistent with the Company’s commitment to the highest quality, medically backed dietary supplement products, PanGenex has engaged two of the nation's leading cardiologists as advisors. Both doctors bring expertise in cardiology, devices, clinical trials, and possess a keen sense for progressive, novel therapies such as ours. We are excited to welcome them both to our team,” states Jim Mosbaugh, COO of PanGenex.

Dr. Steven Yakubov is an interventional cardiologist, Director of the Cardiac Catheterization Laboratory at Marion General Hospital and Medical Director of the MidWest Cardiology Research Foundation. Dr. Yakubov has participated in more than 75 clinical trials involving interventional cardiology, peripheral vascular medicine and electrophysiology. Dr. Yakubov is also a valued advisor for BioStar Ventures, a venture capital partnership created by physicians and medical business leaders to invest primarily in early-stage medical devices.

Dr. Mark Turco is an interventional cardiologist and a member of Cardiovascular Consultants, PA. Dr. Turco has significant experience in clinical trial research with an emphasis on acute coronary syndromes, interventional cardiology drugs and devices, and myocardial infarction. Dr. Turco works closely with the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions on guidelines, CMS policy, and other advocacy.

As Trustee for The Society for Cardiovascular Angiography and Interventions (SCAI), the primary professional association for invasive and interventional cardiologists, Dr. Turco will help PanGenex to continue to promote the benefits provided by Calci-CLEAR™, LIPIDEME™, and Omeganol™.

[Jonathan Devine]

Worldwide Demand for PanGenex Nutraceutical Products Continues
PanGenex Corporation (Pink Sheets: PGCX) (“PanGenex” or “the Company”) announced today that without marketing emphasis, orders from Puerto Rico, Australia, Canada, Mexico and Brazil continue to be received by the Company. The inquires and orders outside the United States are being submitted by medical practitioners who have a professional relationship with doctors who are familiar with Calci-CLEAR in America.
“There can be no better testimonial than a doctor to doctor recommendation and that is what is occurring at PanGenex,” stated John Stanton, Chairman.